MA29683B1 - Combinaison pour traiter une hyperplasie benigne de la prostate - Google Patents

Combinaison pour traiter une hyperplasie benigne de la prostate

Info

Publication number
MA29683B1
MA29683B1 MA30335A MA30335A MA29683B1 MA 29683 B1 MA29683 B1 MA 29683B1 MA 30335 A MA30335 A MA 30335A MA 30335 A MA30335 A MA 30335A MA 29683 B1 MA29683 B1 MA 29683B1
Authority
MA
Morocco
Prior art keywords
hyperplasie
benign
prostate
treating
combination
Prior art date
Application number
MA30335A
Other languages
English (en)
Inventor
Helmut Haning
Peter Serno
Erwin Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA29683B1 publication Critical patent/MA29683B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Combinaison pour traiter une hyperplasie bénigne de la prostate Cette invention se rapporte à un nouveau procédé pour le traitement des symptômes associés à l'hyperplasie bénigne de la prostate couramment employé pour traiter médicalement l'hyperplasie bénigne de la prostate. Ceci nécessite l'utilisation concomitante : (1) d'un antagoniste des récepteurs (alpha)1-adrénergiques dans une formulation à libération contrôlée ou d'un inhibiteur de la 5-(alpha) réductase et (2) d'un inhibiteur de la PDE 5 spécifique de la GMPc dans une formulation à libération contrôlée ou d'un inhibiteur de la PDE 5 spécifique de la GMPc avec une longue demi-vie.
MA30335A 2005-04-13 2007-10-29 Combinaison pour traiter une hyperplasie benigne de la prostate MA29683B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (de) 2005-04-13 2005-04-13 Kombination zur Therapie bei benigner Prostatahyperplasie

Publications (1)

Publication Number Publication Date
MA29683B1 true MA29683B1 (fr) 2008-08-01

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30335A MA29683B1 (fr) 2005-04-13 2007-10-29 Combinaison pour traiter une hyperplasie benigne de la prostate

Country Status (22)

Country Link
EP (1) EP1888075A1 (fr)
JP (1) JP2008535877A (fr)
KR (1) KR20080007252A (fr)
CN (1) CN101193638A (fr)
AR (1) AR053575A1 (fr)
AU (1) AU2006233567A1 (fr)
BR (1) BRPI0610634A2 (fr)
CA (1) CA2605224A1 (fr)
CR (1) CR9427A (fr)
DE (1) DE102005016981A1 (fr)
DO (1) DOP2006000074A (fr)
GT (1) GT200600145A (fr)
IL (1) IL186604A0 (fr)
MA (1) MA29683B1 (fr)
MX (1) MX2007012567A (fr)
PE (1) PE20061338A1 (fr)
RU (1) RU2007141518A (fr)
SV (1) SV2008002477A (fr)
TN (1) TNSN07385A1 (fr)
TW (1) TW200716122A (fr)
UY (1) UY29473A1 (fr)
WO (1) WO2006108519A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO2007047282A1 (fr) * 2005-10-12 2007-04-26 Lilly Icos Llc Traitement d'une hypertrophie benigne de la prostate et de symptomes dans les voies urinaires inferieures
EP1968705A1 (fr) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Combinaison pharmaceutique d'un inhibiteur de pde-5 et d'un inhibiteur de 5-alpha reductase
WO2008005039A1 (fr) * 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions solides comprenant du tadalafil et au moins un véhicule
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
SI2222300T1 (sl) 2007-12-13 2014-11-28 Vanda Pharmaceuticals Inc. Postopek in sestavek za zdravljenje stanja, posredovanega z receptorjem serotonina
JP5729808B2 (ja) * 2007-12-13 2015-06-03 ヴァンダ ファーマシューティカルズ インコーポレイテッド αアドレナリン受容体介在状態を治療する方法及び組成物
US8654746B2 (en) 2010-04-26 2014-02-18 Intel Corporation Method, apparatus and system for fast session transfer for multiple frequency band wireless communication
WO2013123965A1 (fr) * 2012-02-20 2013-08-29 Synthon Bv Formulation pharmaceutique à dose fixe
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
EA039091B1 (ru) * 2013-06-28 2021-12-02 Ханми Фарм. Ко., Лтд. Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
KR20210103589A (ko) 2013-07-23 2021-08-23 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
WO2016003181A1 (fr) * 2014-06-30 2016-01-07 한미약품 주식회사 Préparation composite comprenant une couche de revêtement par film contenant un principe actif
WO2016003180A1 (fr) * 2014-06-30 2016-01-07 한미약품 주식회사 Preparation composite comprenant une couche de revêtement pelliculaire contenant un inhibiteur de la 5-alpha-réductase, et procédé pour produire la préparation composite
PL3150201T3 (pl) * 2014-06-30 2020-09-21 Hanmi Pharm. Co., Ltd. Preparat kompozytowy zawierający błonową warstwę powlekającą zawierającą inhibitor 5-reduktazy i sposób wytwarzania preparatu kompozytowego
WO2016081772A1 (fr) * 2014-11-20 2016-05-26 Allergan, Inc. Procédés et compositions comprenant de la desmopressine combinée à un antagoniste du récepteur alpha-adrénergique
AU2017244269A1 (en) * 2016-03-31 2018-10-11 Hanmi Pharm. Co., Ltd. Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate
KR101835506B1 (ko) * 2016-10-25 2018-03-07 주식회사 에스텍파마 두타스테리드와 타다라필을 함유하는 속효성 복합정제
CN108066347B (zh) * 2016-11-16 2021-02-02 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
BRPI0610634A2 (pt) 2010-07-13
JP2008535877A (ja) 2008-09-04
CN101193638A (zh) 2008-06-04
KR20080007252A (ko) 2008-01-17
PE20061338A1 (es) 2007-01-28
AU2006233567A1 (en) 2006-10-19
SV2008002477A (es) 2008-02-08
DE102005016981A1 (de) 2006-10-19
RU2007141518A (ru) 2009-05-20
TNSN07385A1 (en) 2009-03-17
CR9427A (es) 2007-12-17
DOP2006000074A (es) 2006-10-15
WO2006108519A1 (fr) 2006-10-19
UY29473A1 (es) 2006-11-30
EP1888075A1 (fr) 2008-02-20
CA2605224A1 (fr) 2006-10-19
MX2007012567A (es) 2007-12-10
GT200600145A (es) 2007-04-10
IL186604A0 (en) 2008-01-20
AR053575A1 (es) 2007-05-09
TW200716122A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
MA29683B1 (fr) Combinaison pour traiter une hyperplasie benigne de la prostate
MA31150B1 (fr) Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE509019T1 (de) Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TR200302309T4 (tr) Fosfodiesterazın yararlı inhibitörleri olarak beta-karbolin türevleri.
NO20072322L (no) Laktamforbindelser og anvendelse derav som farmasoytiske midler
TW200505903A (en) CGRP receptor antagonists
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
HRP20050529A2 (en) Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
EP1613368A4 (fr) Antagonistes des recepteurs du cgrp a base de carboxamide spirohydantoine
EA200700251A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
ATE483692T1 (de) Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
WO2007016087A3 (fr) Antagonistes des récepteurs de cgrp de benzodiazépine hétérocyclique
MA29880B1 (fr) Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires.
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.